Caroline Perry
Overview
Explore the profile of Caroline Perry including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
771
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Beier U, Hartung E, Concors S, Hernandez P, Wang Z, Perry C, et al.
Metabolomics
. 2020 May;
16(5):65.
PMID: 32367163
To examine metabolic differences between renal allograft acute cellular rejection (ACR) and ischemic-reperfusion injury (IRI), we transplanted MHC-mismatched kidneys and induced 28 min warm-IRI, and collected the ACR and IRI...
12.
Glassner K, Oglat A, Duran A, Koduru P, Perry C, Wilhite A, et al.
J Dig Dis
. 2020 Apr;
21(5):264-271.
PMID: 32324969
Objective: There are limited data on using more than one biologic or small molecule drug combined to treat patients with inflammatory bowel disease. The aim of our study was to...
13.
Casciano J, Perry C, Cohen-Nowak A, Miller K, Vande Voorde J, Zhang Q, et al.
Br J Cancer
. 2020 Jan;
122(6):868-884.
PMID: 31942031
Background: Recent studies have suggested that fatty acid oxidation (FAO) is a key metabolic pathway for the growth of triple negative breast cancers (TNBCs), particularly those that have high expression...
14.
ORiordan W, Tiffany C, Scangarella-Oman N, Perry C, Hossain M, Ashton T, et al.
Antimicrob Agents Chemother
. 2017 Apr;
61(6).
PMID: 28373199
Gepotidacin is a novel, first-in-class, triazaacenaphthylene antibacterial agent which has activity against causative pathogens of acute bacterial skin and skin structure infections (ABSSSIs). This phase 2, randomized, 2-part, multicenter, dose-ranging,...
15.
Nauck M, Stewart M, Perkins C, Jones-Leone A, Yang F, Perry C, et al.
Diabetologia
. 2015 Nov;
59(2):266-74.
PMID: 26577795
Aims/hypothesis: Additional safe and effective therapies for type 2 diabetes are needed, especially ones that do not cause weight gain and have a low risk of hypoglycaemia. The present study...
16.
Weissman P, Carr M, Ye J, Cirkel D, Stewart M, Perry C, et al.
Diabetologia
. 2014 Sep;
57(12):2475-84.
PMID: 25208756
Aims/hypothesis: The aim of this study was to compare the efficacy and safety of once-weekly albiglutide with once-daily insulin glargine (A21Gly,B31Arg,B32Arg human insulin) in patients with type 2 diabetes inadequately...
17.
Darpo B, Zhou M, Matthews J, Zhi H, Young M, Perry C, et al.
Diabetes Ther
. 2014 Jul;
5(2):609.
PMID: 25034668
No abstract available.
18.
Ahren B, Johnson S, Stewart M, Cirkel D, Yang F, Perry C, et al.
Diabetes Care
. 2014 Jun;
37(8):2141-8.
PMID: 24898304
Objective: To compare the efficacy and safety of weekly albiglutide with daily sitagliptin, daily glimepiride, and placebo. Research Design And Methods: Patients with type 2 diabetes receiving metformin were randomized...
19.
Darpo B, Zhou M, Matthews J, Zhi H, Young M, Perry C, et al.
Diabetes Ther
. 2014 Feb;
5(1):141-53.
PMID: 24510375
Introduction: Albiglutide, a selective once-weekly glucagon-like peptide-1 receptor agonist, is being developed for the treatment of type 2 diabetes mellitus. Albiglutide's effect on cardiac repolarization (QTc interval) was assessed in...
20.
Watson J, Whiteside G, Perry C
Drugs
. 2011 Oct;
71(15):2079-89.
PMID: 21985171
Apixaban (Eliquis™), an oral direct factor Xa inhibitor, is being developed by Bristol-Myers Squibb and Pfizer as a therapy for the prevention and/or treatment of thrombotic disorders. Apixaban has been...